Cubist Systematic Strategies LLC Increases Holdings in LivaNova PLC $LIVN

Key Points

• Cubist Systematic Strategies LLC increased its stake in LivaNova PLC by 46.3% in Q1, owning around 249,195 shares valued at approximately $9.8 million at the end of the quarter.
• LivaNova's earnings surpassed estimates, reporting $1.05 earnings per share for Q2, exceeding the consensus estimate of $0.84 by $0.21, and a revenue of $352.5 million, a 10.6% increase year-over-year.
• Wall Street analysts maintain a positive outlook for LivaNova, with an average target price of $59.71 and a majority rating of "Buy", reflecting strong growth potential for the stock.

Cubist Systematic Strategies LLC increased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 46.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 249,195 shares of the company's stock after purchasing an additional 78,830 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.46% of LivaNova worth $9,788,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of LIVN. Nuveen LLC bought a new stake in shares of LivaNova in the first quarter worth about $30,954,000. Hotchkis & Wiley Capital Management LLC lifted its holdings in LivaNova by 100.7% in the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company's stock worth $39,398,000 after buying an additional 503,350 shares during the period. LSV Asset Management lifted its holdings in LivaNova by 278.3% in the first quarter. LSV Asset Management now owns 438,498 shares of the company's stock worth $17,224,000 after buying an additional 322,598 shares during the period. Vanguard Group Inc. lifted its holdings in LivaNova by 13.5% in the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after buying an additional 316,993 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in LivaNova by 146.1% in the first quarter. Wellington Management Group LLP now owns 472,843 shares of the company's stock worth $18,573,000 after buying an additional 280,718 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Needham & Company LLC restated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a report on Wednesday. Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Barclays raised their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $59.71.

LivaNova Stock Down 0.3%

Shares of LIVN stock traded down $0.18 during trading hours on Friday, hitting $57.97. 958,459 shares of the company's stock traded hands, compared to its average volume of 633,219. The stock's fifty day simple moving average is $48.67 and its two-hundred day simple moving average is $43.68. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $58.42. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -14.90 and a beta of 0.97. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. During the same period last year, the business earned $0.93 earnings per share. The business's revenue was up 10.6% on a year-over-year basis. On average, analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.